NCT04585347View on ClinicalTrials.gov

Single Dose Study of ALZ-801 Prototype Tablets

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 16, 2015

Primary Completion Date

November 13, 2015

Study Completion Date

November 13, 2015

Conditions

Alzheimer Disease

Interventions

DRUG

ALZ-801 170 mg Fasting

DRUG

ALZ-801 205 mg Fasting

DRUG

ALZ-801 205 mg After Food

DRUG

ALZ-801 342 mg Fasting

Sponsors

Lead Sponsor

Collaborators (1)

Quotient Clinical

All Listed Sponsors

collaborator

Quotient Clinical

OTHER

lead

Alzheon Inc.

INDUSTRY